BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 32473643)

  • 1. Risk factors of distant metastasis after surgery among different breast cancer subtypes: a hospital-based study in Indonesia.
    Anwar SL; Avanti WS; Nugroho AC; Choridah L; Dwianingsih EK; Harahap WA; Aryandono T; Wulaningsih W
    World J Surg Oncol; 2020 May; 18(1):117. PubMed ID: 32473643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM; Zhang BN; Xuan LX; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of Site-Specific Metastases and Surgery in De Novo Stage IV Triple-Negative Breast Cancer: A Population-Based Analysis.
    Gu Y; Wu G; Zou X; Huang P; Yi L
    Med Sci Monit; 2020 Feb; 26():e920432. PubMed ID: 32043484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features and survival analysis of different subtypes of patients with breast cancer brain metastases.
    Bai B; Yuan ZY; Liu DG; Teng XY; Wang SS
    Chin J Cancer; 2010 Apr; 29(4):413-9. PubMed ID: 20346218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes.
    Buonomo OC; Caredda E; Portarena I; Vanni G; Orlandi A; Bagni C; Petrella G; Palombi L; Orsaria P
    PLoS One; 2017; 12(9):e0184680. PubMed ID: 28922402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological features of indonesian breast cancers with different molecular subtypes.
    Widodo I; Dwianingsih EK; Triningsih E; Utoro T; Soeripto
    Asian Pac J Cancer Prev; 2014; 15(15):6109-13. PubMed ID: 25124582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastatic behavior of breast cancer subtypes.
    Kennecke H; Yerushalmi R; Woods R; Cheang MC; Voduc D; Speers CH; Nielsen TO; Gelmon K
    J Clin Oncol; 2010 Jul; 28(20):3271-7. PubMed ID: 20498394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
    Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
    Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
    Sanpaolo P; Barbieri V; Genovesi D
    Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
    Wu SY; Tan Y; Guan YS
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
    Yagata H; Kajiura Y; Yamauchi H
    Breast Cancer; 2011 Jul; 18(3):165-73. PubMed ID: 21290263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
    Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
    J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical characteristics and prognosis of different subtypes of breast cancer].
    Yuan ZY; Wang SS; Zhu MQ; Zheng L; Luo WB; Zhou ZM; Guan ZZ
    Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):456-61. PubMed ID: 19024523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of histotypes on preferential organ-specific metastasis in triple-negative breast cancer.
    Li Y; Su P; Wang Y; Zhang H; Liang Y; Zhang N; Song X; Li X; Li J; Yang Q
    Cancer Med; 2020 Feb; 9(3):872-881. PubMed ID: 31814295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological profiles and clinical management challenges of breast cancer emerging in young women in Indonesia: a hospital-based study.
    Anwar SL; Raharjo CA; Herviastuti R; Dwianingsih EK; Setyoheriyanto D; Avanti WS; Choridah L; Harahap WA; Darwito ; Aryandono T; Wulaningsih W
    BMC Womens Health; 2019 Feb; 19(1):28. PubMed ID: 30728000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological complete response in invasive breast cancer treated by skin sparing mastectomy and immediate reconstruction following neoadjuvant chemotherapy and radiation therapy: Comparison between immunohistochemical subtypes.
    Barrou J; Bannier M; Cohen M; Lambaudie E; Gonçalves A; Bertrand P; Buttarelli M; Opinel P; Sterkers N; Tallet A; Zinzindohoué C; Houvenaeghel G
    Breast; 2017 Apr; 32():37-43. PubMed ID: 28033508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer.
    Jensen MB; Lænkholm AV; Nielsen TO; Eriksen JO; Wehn P; Hood T; Ram N; Buckingham W; Ferree S; Ejlertsen B
    Breast Cancer Res; 2018 Jul; 20(1):79. PubMed ID: 30053900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.